Labor1 1
April 21. 2022

A Hungarian participant will also attend the Washington summit on artificial intelligence

The founder and scientific director of Oncompass Medicine, Dr. István Peták,  a cancer researcher, will attend as a member of the EU delegation the EU-US Summit in Washington, DC, between 25 and 28 April 2022. The summit focuses on the preparation of a single international regulatory framework for AI-based technologies. 

Dr  Petak Istvan Portre7 Foto Falus Kriszta

The EU delegation will be led by Cecilia Bonefeld-Dahl, Director of DigitalEurope, a professional association of 35.000 digital businesses in Europe. The EU delegation involves executives from European technology companies that have achieved outstanding results at international level. Under the leadership of Dr. István Peták, Oncompass Medicine has won several prestigious national and international innovation awards for the development of the Realtime Oncology Treatment Calculator software. Oncompass Medicine 2021 won among others the Future Unicorn Award as Europe's most promising technology company, and most recently, Ursula von der Leyen, President of the European Commission, called Oncompass software the latest revolutionary breakthrough in medicine. 

The delegation of the summit will be hosted by the EU's US Ambassador and will meet with members of the US Congress, relevant White House advisers and representatives of the US State and Commerce Departments. At the Washington meeting, EU and US policymakers discuss a single legal framework for the safe and effective use of artificial intelligence. One of the urgent objectives of the single regulation is to enable technology companies and their solutions to enter the market as quickly as possible on both continents. This is particularly important for medical developments such as the Oncompass Medicine software. 

Dr. István Peták highlighted: "Cancer is the common enemy of humanity, so we must fight it together. The fight against cancer is a priority on both continents. The European Union has recently adopted the "Missionon Cancer" cancer programme, and the United States has launched its "Cancer Moonshot" programme, which is particularly close to President Joe Biden's heart: he lost his first-born son to brain cancer. We, as doctors and researchers, must do our utmost to ensure that the latest discoveries, therapies and solutions reach all patients around the world as quickly as possible. Most medical devices and medicines come to Hungary from the United States. Now a medical device developed by Hungarian researchers is finally coming to the United States."

Dr. István Peták has recently been elected  Professor of Pharmacology at the University of Illinois at Chicago (UIC), the largest medical school in the US. Dr. One of Dr. Peták's main goals is for Oncompass Medicine to set up a spin-out company in the United States, so that they can conquer the US market with their proprietary software. 

Dr. István Peták and his team have developed an artificial intelligence-based calculator software (Realtime Oncology Treatment Calculator) that helps oncologists to select the most effective personalised therapy for each cancer patient by systematising and evaluating molecular diagnostic results. 

Under the leadership of Dr. István Peták, Oncompass Medicine has won several prestigious national and international innovation awards for the development of the Realtime Oncology Treatment Calculator software. In 2019, he received the American Society of Clinical Oncologists (ASCO) Award and won the Get in the Ring! V4 award. In 2020, in addition to the IT Innovation Award, OCM was awarded the Tibor Gyurós Award in Hungary, and in 2021 it won the Future Unicorn Award as Europe's most promising technology company.

previous next

Asco Breakthrough

ASCO Breakthrough Innovations in Oncology

2019 Read more
More

About us

Our story

2003— —2022

Oncompass Medicine is a Hungarian medical enterprise dealing with the development of decision support and diagnostic medical devices that help the personalized treatment of cancer patients. 

More information